

**Sebastiano Intagliata, Ph.D.**

Assistant Professor of Medicinal Chemistry

Department of Drug and Health Sciences

University of Catania

Viale A. Doria 6, 95125 Catania, Italy.

Phone: +39-095-738-4053

E-mail: [s.intagliata@unict.it](mailto:s.intagliata@unict.it)

Skype: s.intagliata

Website: <http://www.dsf.unict.it/docenti/sebastiano.intagliata>**Scopus** Author ID: [56328031500](https://publons.com/authors/56328031500/) <http://orcid.org/0000-0002-0201-1745>

---

**INFORMAZIONI PERSONALI**

Date of birth: 10/09/1987

Place of birth: Siracusa

Nationality: Italian

**BIBLIOMETRIC DATA (source Scopus)**

Total number of publications: 45

Total number of citations: 616

*h*-index: 16**EDUCATION**

Jan. 2013 – Feb. 2016      Doctor of Philosophy in Pharmaceutical Sciences, Department of Drug Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.  
Dissertation title: “New alkylpiperazines as 5-HT<sub>7</sub>R ligands”. Advisor: Prof. Maria N. Modica.

Jan. 2013      Qualified as a Pharmacist in Italy,

Oct. 2006 – July 2012      Master’s degree in Chemistry and Pharmaceutical Technology, Department of Drug Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.  
Dissertation title: “New quinazoline derivatives as potential 5-HT<sub>7</sub>R ligands”. Advisor: Prof. Maria N. Modica.

**RESEARCH EXPERIENCE**

Jul. 2022 – present      Assistant Professor (RTD-b) of Medicinal Chemistry, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.  
Project description: development of novel heme oxygenase 1 (HO-1) inhibitors-based mutual prodrugs as innovative approach in anticancer chemotherapy. Design and synthesis of new  $\sigma$  receptor ligands. Design and synthesis of new HO-1 inhibitors.

Feb. 2022      National Scientific qualification as Associate Professor of Medicinal Chemistry in the Italian higher education system for the disciplinary field 03/D1 - Medicinal, toxicological and nutritional chemistry and

applied technologies.

- Aug. 2019 – Jun. 2022  
Research Associate (RTD-a), Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.  
Project description: design and synthesis of novel multi-target ligands with anticancer activity, as innovative approach to overcome drug resistance in cancer chemotherapy.
- Oct. 2020 – Feb. 2021  
Visiting Researcher, Department of Organic Chemistry, Jagiellonian University Medical College.  
Supervisor: Prof. dr hab. Paweł Zajdel.  
Project description: *in vitro* chemical and metabolic assessment of new 5-FU/HO-1 inhibitor hybrids as potential anticancer drugs.
- Jan. 2020 – Feb. 2020  
Visiting Researcher, Department of Molecular Medicine and Princess Al-Jawhara Center for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain.  
Supervisor: Prof. Khaled Greish.  
Project description: *in vitro* pharmacological evaluation, and nanoformulation testing of new heme oxygenase-1 inhibitors, and their hybrid analogs with anticancer drugs
- Jan. 2017 – June 2019  
Post-Doctoral Associate, Department of Medicinal Chemistry, College of Pharmacy, University of Florida. Gainesville, FL, USA.  
Supervisor: Prof. Christopher R. McCurdy.  
Project description: lead optimization of a highly selective sigma-1 receptor antagonist; design and synthesis of sigma receptor ligands as potential treatments for pain and drug abuse.
- May 2016 – Jan. 2017  
Post-Doctoral Associate, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, Oxford, MS, USA.  
Supervisor: Christopher R. McCurdy.  
Project description: design and synthesis of sigma receptor ligands, and opioid derivatives.
- July 2015 – Sept. 2015  
Visiting scholar working, University of Mississippi, Oxford, MS, USA.  
Supervisor: Christopher R. McCurdy, Ph.D.  
Project description: design and synthesis of new benzo[d]thiazol-2(3H)one based sigma-1 receptor ligands.
- Jan. 2015 – May 2015  
Visiting PhD Student, Institute of Pharmacology of the Polish Academy of Sciences, Department of Medicinal Chemistry, Krakow, Poland.  
Supervisor: Prof. Andrzej J. Bojarski.  
Project description: homology modeling of G-protein-coupled receptors, virtual screening, ligand docking, pharmacophore modeling, theoretical conformational analysis, prediction of physico-chemical, and pharmacokinetic properties of chemical compounds, *in silico* studies of ligand-receptor interactions

## RESEARCH INTERESTS

Currently, my research is focused on the design, and synthesis of novel heme oxygenase 1 (HO-1) inhibitors with peculiar anticancer activity, as well as the development of hybrid compounds obtained by combining the structure of imidazole-based HO-1 inhibitors with sigma receptor ligands and/or anticancer drugs, as an innovative approach to overcome drug resistance as well as to improve cancer chemotherapy. My research interests include medicinal chemistry, drug discovery, structure-based drug design, hit to lead optimization,

organic synthesis.

## GRANT FUNDING

- Piano di incentivi per la ricerca di Ateneo 2020/2022 (Pia.ce.ri.), linea di Intervento 3 “Starting Grant”. Title: Novel polypharmacological agents as innovative cancer treatments, POLYPHARMA-CT. Role: Principal investigator, budget € 5000/year.

## PARTECIPATION IN RESEARCH PROJECTS

- PON R&I funds 2014-2020, CUP: E66C18001320007, AIM1872330, activity 1. Title: New strategies for the development of anticancer agents. Principal Investigator: Prof. Rosario Pignatello.
- Piano di incentivi per la ricerca di Ateneo 2020/2022 (Pia.ce.ri.). Title: Modulazione dell’Eme ossigenasi nella Terapia Antitumorale, META. Principal investigator: Prof. Valeria Pittalà.
- United States Department of Defense DoD, PR161310, contract W81XWH-17-1-0557. Title: Sigma receptor ligands and non-opioid based pain management. Principal Investigators: Christopher McCurdy, Ph.D., FAAPS, and Jay P. McLaughlin, Ph.D.
- FIR 2014 (Finanziamento Ricerca di Ateneo) University of Catania, contract 764AAD. Title: Antioxidants loaded lipid nano-carriers for the treatment of neurodegenerative diseases based on mitochondrial disorders. Principal Investigator: Prof. Giovanni Puglisi.

## PUBLICATIONS

1. Salerno, L.; Sorrenti, V.; Pittalà, V.; Consoli, V.; Modica, M.N.; Romeo, G.; Marrazzo, A.; Giuliano, M.; Zajdel, P.; Vanella, L.; Intagliata S. Discovery of SI 1/20 and SI 1/22 as new mutual prodrugs of 5-fluorouracil and imidazole-based heme oxygenase 1 inhibitor with improved cytotoxicity in DU145 prostate cancer cells. *ChemMedChem*. **2023** Feb 9. doi: 10.1002/cmdc.202300047. Online ahead of print.
2. Nestic de Freitas, L.S.F.; da Silva, C.F.; **Intagliata, S.**; Amata, E.; Salerno, L.; Soeiro, M.N.C. In vitro and in silico analysis of imatinib analogues as anti- Trypanosoma cruzi drug candidates. *Parasitology*. **2023** Jan 12;1-18. doi: 10.1017/S0031182023000057. Online ahead of print.
3. Fallica, A. N.; Ciaffaglione, V.; Modica, M. N.; Pittalà, V.; Salerno, L.; Amata, E.; Marrazzo, A.; Romeo, G.; **Intagliata, S.** Structure-activity relationships of mixed  $\sigma_1R/\sigma_2R$  ligands with antiproliferative and anticancer effects. *Bioorg. Med. Chem.* **2022**, *73*, 117032. doi: 10.1016/j.bmc.2022.117032.
4. Wilson, L.L.; Alleyne, A.R.; Eans, S.O.; Cirino, T.J.; Stacy, H.M.; Mottinelli, M.; **Intagliata, S.**; McCurdy, C.R.; McLaughlin JP. Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain. *Molecules*. **2022**, *27*, 3617. doi: 10.3390/molecules27113617.
5. Ciaffaglione, V.; Consoli, V.; **Intagliata, S.**; Marrazzo, A.; Romeo, G.; Pittalà, V.; Greish, K.; Vanella, L.; Floresta, G.; Rescifina, A.; Salerno, L.; Sorrenti V. Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. *Molecules*. **2022**, *27*, 3220. doi: 10.3390/molecules27103220.
6. Consoli, V.; Sorrenti, V.; Pittalà, V.; Greish, K.; D'Amico, A.G.; Romeo, G.; **Intagliata, S.**; Salerno, L.; Vanella, L. Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells. *Int. J. Mol. Sci.* **2022**, *23*, 5709. doi: 10.3390/ijms23105709.
7. Elkholy, N.; Abdelwaly, A.; Mohamed, K.; Amata, E.; Lombino, J.; Cosentino, G.; **Intagliata, S.**; Helal, M.A. Discovery of 3-(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligands. *Chem. Biol. Drug. Des.* **2022**, *100*, 25-40. doi: 10.1111/cbdd.14047.
8. Popa, R.; Kamble, S.H.; Kanumuri, R.S.; King, T.I.; Berthold, E.C.; **Intagliata, S.**; Sharma, A.; McCurdy, C.R. UPLC-MS/MS method for the quantification of MCI-77, a novel sigma-1 receptor ligand, and its application to pharmacokinetic studies. *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* **2022**, *1196*:123187. doi: 10.1016/j.jchromb.2022.123187.
9. Wilson, L. L.; Eans, S.O.; Ramadan-siraj, I.; Modica, M. N.; Romeo, G.; **Intagliata, S.**; McLaughlin, J.

- P. Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-Allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use. *Int. J. Mol. Sci.*, **2022**, *23*, 615. doi: 10.3390/ijms23020615.
10. Puglia, C.; Santonocito, D.; Romeo, G.; **Intagliata, S.**; Romano, G. L.; Strettoi, E.; Novelli, E.; Ostacolo, C.; Campiglia, P.; Sommella, E. M.; Pignatello, R.; Bucolo, C. Lipid nanoparticles traverse non-corneal path to reach the posterior eye segment: In vivo evidence. *Molecules*. **2021**, *26*, 4673. doi: 10.3390/molecules26154673.
  11. Ciaffaglione, V.; Modica, M. N.; Pittalà, V.; Romeo, G.; Salerno, L.; **Intagliata, S.** Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs. *ChemMedChem*. **2021**, *16*, 3496-3512. doi: 10.1002/cmdc.202100473.
  12. Fallica, A. N.; Sorrenti, V.; D'Amico, A. G.; Salerno, L.; Romeo, G.; **Intagliata, S.**; Consoli, V.; Floresta, G.; Rescifina, A.; D'Agata, V.; Vanella, L.; Pittalà, V. Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent in Vitro Antiproliferative Activity. *J. Med. Chem.* **2021**, *64*, 13373-13393. doi: 10.1021/acs.jmedchem.1c00633.
  13. Fallica, A.N.; Barbaraci, C.; Amata, E.; Pasquinucci, L.; Turnaturi, R.; Dichiarà, M.; **Intagliata, S.**; Gariboldi, M.B.; Marras, E.; Orlandi, V.T.; Ferroni, C.; Martini, C.; Rescifina, A.; Gentile, D.; Varchi, G.; Marrazzo, A. Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents. *J. Med. Chem.* **2021**, *64*, 11597-11613. doi: 10.1021/acs.jmedchem.1c00917.
  14. Romeo, G.; Ciaffaglione, V.; Amata, E.; Dichiarà, M.; Calabrese, L.; Vanella, L.; Sorrenti, V.; Grosso, S.; D'Amico, A.G.; D'Agata, V.; **Intagliata, S.**; Salerno, L. Combination of Heme Oxygenase-1 Inhibition and Sigma Receptor Modulation for Anticancer Activity. *Molecules*. **2021**, *26*, 3860. doi: 10.3390/molecules26133860.
  15. Giurdanella, G.; Longo, A.; Salerno, L.; Romeo, G.; **Intagliata, S.**; Lupo, G.; Distefano, A.; Platania, C.B.M.; Bucolo, C.; Li Volti, G.; Anfuso, C.D.; Pittalà V. Glucose-impaired Corneal Re-epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate. *Antioxidants*. **2021**, *10*, 831. doi: 10.3390/antiox10060831.
  16. Ben Khalaf, N., Pham, S., Romeo, G., Abdelghany, S., **Intagliata, S.**, Sedillo, P., Salerno, L., Gonzales, J., Fathallah, D.M., Perkins, D.J., Hurwitz, I., Pittalà, V. A computer-aided approach to identify novel Leishmania major protein disulfide isomerase inhibitors for treatment of leishmaniasis. *J Comput Aided Mol Des*. **2021**, *35*, 297-314. doi: 10.1007/s10822-021-00374-w.
  17. Salerno, L.; Vanella, L.; Sorrenti, V.; Consoli, V.; Ciaffaglione, V.; Fallica, A. N.; Canale, V.; Zajdel, P.; Pignatello, R.; **Intagliata, S.** Novel mutual prodrug of 5-fluorouracil and heme oxygenase 1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation. *J. Enzyme Inhib. Med. Chem.* **2021**, *36*, 1378-1386. doi: 10.1080/14756366.2021.1928111.
  18. Fallica, A. N.; Pittalà, V.; Modica, M. N.; Salerno, L.; Romeo, G.; Marrazzo, A.; Helal, M.; **Intagliata, S.** Recent Advances in the Development of Sigma Receptors Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. *J. Med. Chem.* **2021**, *64*, 7926-7962. doi: 10.1021/acs.jmedchem.0c02265.
  19. Romeo, G.; Bonanno, F.; Wilson, L. L.; Arena, E.; Modica, M.N.; Pittalà, V.; Salerno, L.; Prezzavento, O.; McLaughlin, J. P.; **Intagliata, S.** Development of New Benzylpiperazine Derivatives as  $\sigma$  Receptor Ligands with *in Vivo* Antinociceptive and Anti-allodynic Effects. *ACS Chem. Neurosci.* **2021**, *12*, 2003-2012. doi: 10.1021/acschemneuro.1c00106.
  20. **Intagliata, S.**, Spadaro, A., Lorenti, M., Panico, A., Siciliano, E.A., Barbagallo, S., Macaluso, B., Kamble, S.H., Modica, M.N., Montenegro, L. In Vitro Antioxidant and Anti-Glycation Activity of Resveratrol and Its Novel Triester with Trolox. *Antioxidants* **2021**, *10*, 12. doi: 10.3390/antiox10010012.
  21. Ianni, F.; Carotti, A.; **Intagliata, S.**; Macchiarulo, A.; Chankvetadze, B.; Pittalà, V.; Sardella, R. Laboratory-Scale Semipreparative Enantioresolution of Phenylethanol-Azole Heme Oxygenase-1 Inhibitors. *Chromatographia*. **2020**, *83*, 1509-1515. doi: 10.1007/s10337-020-03972-2.
  22. Popa R.; Kamble, S.H.; Kanumuri, R.S.; King, T.I.; Berthold, E.C.; **Intagliata, S.**; Sharma, A.; McCurdy CR. Bioanalytical Method Development and Pharmacokinetics of MCI-92, a Sigma-1 Receptor Ligand. *J Pharm Biomed Anal.* **2020**, *191*, 113610. doi: 10.1016/j.jpba.2020.113610.
  23. **Intagliata, S.**; Agha, H.; Kopajtic, T.A.; Katz, J.L.; Kamble, S.H.; Sharma, A.; Avery, B.A.; McCurdy, C.R. Exploring 1-Adamantanamine as an Alternative Amine Moiety for Metabolically Labile Azepane Ring in Newly Synthesized Benzo[d]thiazol-2(3H)one  $\sigma$  Receptor Ligands. *Med. Chem. Res.*, **2020**, *29*, 1697-1706. doi: 10.1007/s00044-020-02597-2.

24. **Intagliata, S.**; Sharma, A.; King, T.I.; Mesangeau, C.; Seminerio, M.; Chin, F.T.; Wilson, L.L.; Matsumoto, R.R.; McLaughlin, J.P.; Avery, B.A.; McCurdy C.R. Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo. *AAPS J.*, **2020**, *22*, 94. doi: 10.1208/s12248-020-00472-x.
25. Floresta, G.; Carotti, A.; Ianni, F.; Sorrenti, V.; **Intagliata, S.**; Rescifina, A.; Salerno, L.; Di Michele, A.; Sardella, R.; Pittalà, V. Chromatographic resolution of phenylethanol-azole racemic compounds highlighted stereoselective inhibition of heme oxygenase-1 by (R)-enantiomers. *Bioorganic Chemistry*, **2020**, *99*, 103777. doi: 10.1016/j.bioorg.2020.103777.
26. Khan, H.; Pervaiz, A.; Intagliata, S.; Das, N.; Nagulapalli Venkata, K.; Atanasov, A.G.; Najda, A.; Nabavi, S.M.; Wang, D.; Pittalà, V.; Bishayee, A. The analgesic potential of glycosides derived from medicinal plants. *Daru*, **2020**, Feb 14. doi: 10.1007/s40199-019-00319-7.
27. **Intagliata, S.**; Helal, M.A.; Materia, L.; Pittalà, V.; Salerno, L.; Marrazzo, A.; Cagnotto, A.; Salmona, M.; Modica, M.N.; Romeo, G. Synthesis and molecular modelling studies of new 1,3-diaryl-5-oxo-proline derivatives as endothelin receptor ligands. *Molecules*, **2020**, *25*, 185. doi: 10.3390/molecules25081851.
28. Ciaffaglione, V.; **Intagliata, S.**; Pittalà, V.; Marrazzo, A.; Sorrenti, V.; Vanella, L.; Rescifina, A.; Floresta, G.; Sultan, A.; Greish, K.; Salerno, L. New arylethanolimidazole derivatives as HO-1 inhibitors with cytotoxicity against MCF-7 breast cancer cells. *Int. J. Mol. Sci.*, **2020**, *21*, 1923. doi: 10.3390/ijms21061923.
29. **Intagliata, S.**; Salerno, L.; Ciaffaglione, V.; Leonardi, C.; Fallica, A.N.; Carota, G.; Amata, E.; Marrazzo, A.; Pittalà, V.; Romeo, G. Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors. *Eur. J. Med. Chem.*, **2019**, *183*, 111703. doi: 10.1016/j.ejmech.2019.111703.
30. Romeo, G.; Salerno, L.; Pittalà, V.; Candido, M.; **Intagliata, S.**; Amata, E.; Salmona, M.; Cagnotto, A.; Rescifina, A.; Floresta, G.; Modica, M.N. [1]Benzothieno[3,2-d]pyrimidine derivatives as ligands for the serotonergic 5-HT7 receptor. *Eur. J. Med. Chem.*, **2019**, *183*, 111690. doi: 10.1016/j.ejmech.2019.111690.
31. Carota, G.; Raffaele, M.; Sorrenti, V.; Salerno, L.; Pittalà, V.; Intagliata, S. Ginseng and heme oxygenase 1: The link between an old herb and a new protective system. *Fitoterapia*, **2019**, *139*, 104370. doi: 10.1016/j.fitote.2019.104370.
32. **Intagliata, S.**; Modica, M.N.; Santagati, L.M.; Montenegro, L. Strategies to Improve Resveratrol Systemic and Topical Bioavailability: An Update. *Antioxidants*. **2019**, *8*, 244. doi: 10.3390/antiox8080244.
33. Romeo, G.; Prezzavento, O.; **Intagliata, S.**; Pittalà, V.; Modica, M.N.; Marrazzo, A.; Turnaturi, R.; Parenti, C.; Chiechio, S.; Arena, E.; Campisi, A.; Sposito, G.; Salerno, L. Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands. *Eur. J. Med. Chem.*, **2019**, *174*, 226. doi: 10.1016/j.ejmech.2019.04.056.
34. Sorrenti, V.; Raffaele, M.; Vanella, L.; Acquaviva, R.; Salerno, L.; Pittalà, V.; **Intagliata, S.**; Di Giacomo, C. Protective Effects of Caffeic Acid Phenethyl Ester (Cape) and Novel Cape Analogue as Inducers of Heme Oxygenase-1 in Streptozotocin-Induced Type 1 Diabetic Rats. *Int. J. Mol. Sci.* **2019**, *20*. 2441. doi: 10.3390/ijms20102441.
35. **Intagliata, S.**; Alsharif, W.F.; Mesangeau, C.; Fazio, N.; Seminerio, M.J.; Xu, Y.T.; Matsumoto, R.R.; McCurdy, C.R. Benzimidazolone-based selective  $\sigma_2$  receptor ligands: Synthesis and pharmacological evaluation. *Eur. J. Med. Chem.*, **2019**, *165*, 250. doi: 10.1016/j.ejmech.2019.01.019.
36. Nicholson, H.E.; Alsharif, W.F.; Comeau, A.B.; Mesangeau, C.; **Intagliata, S.**; Mottinelli, M.; McCurdy, C.R.; Bowen, W.D. Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives. *J. Pharmacol. Exp. Ther.*; **2019**, *368*, 272. doi: 10.1124/jpet.118.253484.
37. Montenegro, L.; Panico, A.M.; Santagati, L.M.; Siciliano, E.A.; **Intagliata, S.**; Modica, M.N. Solid Lipid Nanoparticles Loading Idebenone Ester with Pyroglutamic Acid: In Vitro Antioxidant Activity and In Vivo Topical Efficacy. *Nanomaterials*, **2019**, *9*, 43. doi: 10.3390/nano9010043.
38. Cirino, T.J.; Eans, S.O.; Medina, J.M.; Wilson, L.L.; Mottinelli, M.; **Intagliata, S.**; McCurdy, C.R.; McLaughlin, J.P. Characterization of Sigma 1 Receptor (S1R) antagonist CM-304 and its analog, AZ-66: Novel therapeutics against allodynia and induced pain. *Front. Pharmacol.*, **2019**, *10*, 678. doi: 10.3389/fphar.2019.00678.

39. Pittalà, V.; Vanella, L.; Maria Platania, C.B.; Salerno, L.; Raffaele, M.; Amata, E.; Marrazzo, A.; Floresta, G.; Romeo, G.; Greish, K.; **Intagliata, S.**; Bucolo, C.; Sorrenti, V. Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents. *Future Med. Chem.* **2019**, *11*, 1523-1536. doi: 10.4155/fmc-2018-0448.
40. Modica, M.N.; Lacivita, E.; **Intagliata, S.**; Salerno, L.; Romeo, G.; Pittalà, V.; Leopoldo, M. Structure-Activity Relationships and Therapeutic Potentials of 5-HT<sub>7</sub> Receptor Ligands: An Update. *J. Med. Chem.*, **2018**, *61*, 8475. doi: 10.1021/acs.jmedchem.7b01898.
41. Sorrenti, V.; Pittalà, V.; Romeo, G.; Amata, E.; Dichiarà, M.; Marrazzo, A.; Turnaturi, R.; Prezzavento, O.; Barbagallo, I.; Vanella, L.; Rescifina, A.; Floresta, G.; Tibullo D.; Di Raimondo, F.; **Intagliata, S.**; Salerno, L. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines. *Eur. J. Med. Chem.*, **2018**, *158*, 937. doi: 10.1016/j.ejmech.2018.09.048.
42. Greish, K.F.; Salerno, L.; Al Zahrani, R.; Amata, E.; Modica, M.N.; Romeo, G.; Marrazzo, A.; Prezzavento, O.; Sorrenti, V.; Rescifina, A.; Floresta, G.; **Intagliata, S.**; Pittalà, V. Novel Structural Insight into Inhibitors of Heme Oxygenase-1 (HO-1) by New Imidazole-Based Compounds: Biochemical and In Vitro Anticancer Activity Evaluation. *Molecule*, **2018**, *23*, 1209. doi: 10.3390/molecules23051209.
43. **Intagliata, S.**; Modica, M.N.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A.; Salmona, M.; Kurczab, R.; Romeo, G. New *N*- and *O*-arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT<sub>7</sub> and 5-HT<sub>1A</sub> receptor ligands: Synthesis, structure-activity relationships, and molecular modeling studies. *Bioorg. Med. Chem.*, **2017**, *25*, 1250. doi: 10.1016/j.bmc.2016.12.039.
44. **Intagliata, S.**; Modica, M.N.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A.; Salmona, M.; Romeo, G. Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT<sub>7</sub>R selective ligands over 5-HT<sub>1A</sub>R. *Bioorg. Med. Chem. Lett.*, **2016**, *26*, 4052. doi: 10.1016/j.bmcl.2016.06.080.
45. Modica, M.N.; **Intagliata, S.**; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A.; Salmona, M.; Romeo, G. Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptor ligands. *Bioorg. Med. Chem. Lett.*, **2015**, *25*, 1427. doi: 10.1016/j.bmcl.2015.02.042.
46. Salerno, L.; Pittalà, V.; Modica, M.N.; Siracusa, M.A.; **Intagliata, S.**; Cagnotto, A.; Salmona, M.; Kurczab, R.; Bojarski, A.J.; Romeo, G. Structure-activity relationships and molecular modeling studies of novel arylpiperazinylalkyl 2-benzoxazolones and 2-benzothiazolones as 5-HT<sub>7</sub> and 5-HT<sub>1A</sub> receptor ligands. *Eur. J. Med. Chem.*, **2014**, *85*, 716. doi: 10.1016/j.ejmech.2014.08.023.

## INVITED LECTURE

- Seminar entitled "Targeting Heme Oxygenase 1 with Imidazole-based Inhibitors to Improve Cancer Chemotherapy" delivered during the Polish Pharmaceutical Society, Krakow Branch Meeting at the Faculty of Pharmacy, Jagiellonian University Medical College on the February 10, **2021**, Krakow, Poland.

## ORAL PRESENTATIONS AT SCIENTIFIC MEETINGS

- Salerno, L.; Pittalà, V.; Sorrenti, V.; Vanella, L.; Zajdel, P.; Giuliano, M.; **Intagliata, S.** New 5-fluorouracil and heme oxygenase 1 inhibitor mutual prodrugs with in vitro anticancer activity towards colon cancer cells. AMYC-Biomed 2021, Nov. 3-5, **2021**, Virtual Conference, Med. Chem. Oral Comm. 7.
- Salerno, L.; Ciaffaglione, V.; Vanella, L.; Sorrenti, V.; Consoli, V.; Canale, V.; Zajdel, P.; Giuliano, M.; **Intagliata, S.** Development of Mutual Prodrugs of 5-Fluorouracil and Heme Oxygenase 1 Inhibitor as Anticancer Agents. XXVII Congresso Nazionale della Società Chimica Italiana, Sept. 14-23, **2021**, Virtual Conference, FAR OR028.
- **Intagliata, S.**; Loredana, S.; Pittalà, V.; Modica, M.N.; Arena, E.; Wilson, L.L.; McLaughlin, J.P.; Prezzavento, O.; Romeo, G. Synthesis, binding, and functional properties of new benzylpiperazine derivatives as selective  $\sigma_1$  receptor ligands. Autumn Meeting for Young Chemists in Biomedical

Sciences, Virtual Conference. Oct. 13-14, **2020**.

- **Intagliata, S.**; Wilson, L.; Alleyne, A.; Stacy, H.M.; Kamble, S.H.; Sharma, A.; Cano, J.; Kawesa, T.; Toll, L.; Avery, B.A.; McLaughlin, J.P.; McCurdy, C.R. Novel benzothiazolones and benzoxazolones-based  $\sigma$  receptor ligands: synthesis and preliminary pharmacological evaluation against allodynia. Merck Young Chemists' Symposium. Nov. 25-27, **2019**, Rimini, Italia, OR07.
- **Intagliata, S.**; Wilson, L.; Alleyne, A.; Stacy, H.M.; Kamble, S.H.; Sharma, A.; Cano, J.; Kawesa, T.; Toll, L.; Avery, B.A.; McLaughlin, J.P.; McCurdy, C.R. Synthesis and preliminary pharmacological evaluation of new  $\sigma$  receptor ligands with anti-neuropathic pain effects in mice. 2019 CNPD3 UF Drug Discovery Symposium. Apr. 25-26, **2019**, Gainesville, Florida, USA, pag. 47, 3.
- **Intagliata, S.**; Modica, M.N.; Romeo, G.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto A. New alkylpiperazines as 5-HT<sub>7</sub>R ligands. XXV Congresso della Società Chimica Italiana. SCI-2014. Sept. 7-12, **2014**, Arcavacata di Rende, Cosenza, Italia, P-305.

## CONTRIBUTIONS AT SCIENTIFIC MEETINGS

- **Intagliata, S.**; Virzi, N.; Fallica, A. N.; Consoli, V.; Vanella, L.; Sorrenti, V.; Salerno, L.; Floresta, G.; Rescifina, A.; Pittalà, V. Development of a ligand-based approach for the identification of new heme oxygenase-1 inhibitors. 27th National Meeting in Medicinal Chemistry (NMMC27), Sept. 11-14, 2022, Bari, Italia. PO-045. *Poster presentation*.
- Virzi, N.F.; Fallica, A. N.; Sorrenti, V.; Consoli, V.; Burò, I.; Vanella, L.; Salerno, L.; Romeo, G.; **Intagliata, S.**; Pittalà, V. Synthesis and biological evaluation of novel heme oxygenase-1 modulators as potential ferroptosis inducers. 27th National Meeting in Medicinal Chemistry (NMMC27), Sept. 11-14, 2022, Bari, Italia. PO-079. *Poster presentation*.
- Ciaffaglione, V.; Salerno, L.; Pittalà, V.; Modica, M. N.; Romeo, G.; Marrazzo, A.; Zajdel, P.; Consoli, V.; Sorrenti, V.; Vanella, L.; **Intagliata, S.** Development of 5-fluorouracil and heme oxygenase 1 inhibitor mutual prodrugs as an innovative strategy to develop novel anticancer agents. Workshop Pharmaday 2022, 2<sup>a</sup> edizione, June 1, **2022**, Catania, Italia, CFA PO04. *Poster presentation*.
- **Intagliata, S.**; Modica, M. N.; Salerno, L.; Pittalà, V.; Amata, E.; Marrazzo, A.; Wilson, L. L.; McLaughlin, J. P.; Romeo, G. New benzylpiperazine derivatives with high affinity for the sigma-1 receptor and antinociceptive and anti-allodynic effects in vivo. Workshop Pharmaday 2022, 2<sup>a</sup> edizione, June 1, **2022**, Catania, Italia, CFA PO04. *Poster presentation*.
- **Intagliata, S.** Wilson, L.L.; Eans, O. S.; Modica, M.N.; Barbaraci, C.; Marrazzo, C.; Romeo, G.; McLaughlin, J.P. Investigation of the antinociceptive and anti-allodynic effects of the sigma-1 receptor ligand S11/28 in mice. Physiopathology of Sigma-1 Receptors, Third European Symposium sponsored by ESTEVE, Oct. 7-9, **2021**, Bari, Italia, Poster 1. *Poster presentation*.
- Barbaraci, C.; Leotta, C. G.; Giurdanella, G.; Longo, A.; **Intagliata, S.**; Pitari, G. M.; Anfuso, D. C.; Amata, E.; Marrazzo, A. Preliminary study of Haloperidol metabolite II valproate ester MRJF22 enantiomers as potential multifunctional agents against uveal melanoma. Physiopathology of Sigma-1 Receptors, Third European Symposium sponsored by ESTEVE, Oct. 7-9, **2021**, Bari, Italia, Oral 21. *Oral presentation*.
- Ciaffaglione, V.; **Intagliata, S.**; de Freitas L.S.F.N., Soeiro, M.N.C.; Salerno, L. New imatinib-based analogues of benznidazole as anti-Trypanosoma cruzi agents for the treatment of Chagas disease. XXVII Congresso Nazionale della Società Chimica Italiana, Sept. 14-23, **2021**, Virtual Conference, FAR PO005. *Poster presentation*.
- Floresta, G.; Fallica, A. N.; Salerno, L.; Sorrenti, V.; **Intagliata, S.**; Rescifina, A.; Pittalà, V. Structure-Guided Fragment-Based Approach to Identify New Heme Oxygenase-1 Inhibitors. XXVII Congresso Nazionale della Società Chimica Italiana, Sept. 14-23, **2021**, Virtual Conference, FAR PO055. *Poster presentation*.
- Romeo, G.; Bonanno, F.; Wilson, L.L.; Arena, E.; Modica, M.N.; Pittalà, V.; Loredana, S.; Prezzavento, O.; McLaughlin, J.P.; **Intagliata, S.** New benzylpiperazines as sigma-1 receptor antagonist with pharmacological effects in mice. 13th Young Medicinal Chemist's Symposium - Nuove Prospettive in Chimica Farmaceutica. Apr. 26-29, **2021**. P38, *Poster presentation*.
- Romeo, G.; Ciaffaglione, V.; Amata, E.; Dichiarà, M.; Consoli, V.; Sorrenti, V.; Grosso, S.; D'Amico, A. G.; **Intagliata, S.**; Salerno, L. Combination of heme oxygenase-1 inhibition and sigma receptor

- affinity for anticancer activity. 13th Young Medicinal Chemist's Symposium - Nuove Prospettive in Chimica Farmaceutica. Apr. 26-29, **2021**. P15, *Poster presentation*.
- **Intagliata, S.**; Loredana, S.; Pittalà, V.; Modica, M.N.; Arena, E.; Wilson, L.L.; McLaughlin, J.P.; Prezzavento, O.; Romeo, G. New benzylpiperazine derivatives as selective  $\sigma_1$  receptor ligands: synthesis, in vitro and in vivo pharmacological characterization. Italian Young Medicinal Chemistry Virtual Meeting. July 22-24, **2020**. PO26. *Poster presentation*.
  - Barbaraci, C.; Dichiarà, M.; Fallica, A.N.; Ciaffaglione, V.; **Intagliata, S.**; Marrazzo, A. Sigma-HDACi hybrid molecules as potential therapeutic treatment for uveal melanoma: design, synthesis and preliminary results. Workshop della Sezione Sicilia, SCI 2020. Dec. 3, **2020**, Messina, Italia. OC9. *Oral presentation*.
  - Fallica, A.N.; Ciaffaglione, V.; **Intagliata, S.**; Barbaraci, C.; Dichiarà, M.; Sorrenti, V.; Pittalà, V. Targeting the heme oxygenase system with novel azole-based inhibitors possessing an amide function. Workshop della Sezione Sicilia, SCI 2020. Dicembre 3, **2020**, Messina, Italia. P13. *Poster presentation*.
  - **Intagliata, S.**; Loredana, S.; Pittalà, V.; Modica, M.N.; Arena, E.; Wilson, L.L.; McLaughlin, J.P.; Prezzavento, O.; Romeo, G. New benzylpiperazine derivatives as selective  $\sigma_1$  receptor ligands: synthesis, in vitro and in vivo pharmacological characterization. Italian Young Medicinal Chemistry Virtual Meeting (#IYMCVMEET). July 22-24, **2020**. PO26. *Poster presentation*.
  - Fallica, A. N.; Pittalà, V.; Rescifina, A.; Ciaffaglione, V.; **Intagliata, S.**, Floresta, G.; Rational design and synthesis of heme oxygenase 2 (HO-2) inhibitors by targeting the secondary hydrophobic pocket of the HO-2 western region. Italian Young Medicinal Chemistry Virtual Meeting (#IYMCVMEET). July 22-24, **2020**. P39. *Poster presentation*.
  - Salerno, L.; **Intagliata, S.** Inhibition of heme oxygenase-1 to improve cancer therapy. The 24th World Congress on Advances in Oncology, and 24th International Symposium on Molecular Medicine. Oct. 10-12, **2019**, Sparta, Greece. S48, 273. *Oral presentation*.
  - **Intagliata, S.**; Wilson, L.; Alleyne, A.; Stacy, H.M.; Kamble, S.H.; Sharma, A.; Cano, J.; Kawesa, T.; Toll, L.; Avery, B.A.; McLaughlin, J.P.; McCurdy, C.R. Discovery of new 6-substituted-2(3H)-benzothiazolones and 6-substituted-2(3H)-benzoxazolones: novel  $\sigma$ Rs ligands to treat neuropathic pain. EFMC-ACSMEDI Frontiers 2019- Joint symposium on Medicinal Chemistry Frontiers, June 10-13, **2019**, Cracovia, Poland. PO34. *Poster presentation*.
  - Obeng, S.; **Intagliata, S.**; Mottinelli, M.; Restrepo, L.F.; Patel, A.; Wilson, L. L.; Taylor, V. A.; Reeves, M. E.; Pennington, A. E.; McCurdy, C. R.; McMahan, L. R.; Hiranita T. CM304 a sigma1 receptor antagonist enhances the antinociceptive effects of the cannabinoid receptor agonist CP55,940 but not that of morphine in mice. 11th Annual Behavior, Biology, and Chemistry: Translational Research in Addiction. Mar. 2-3, **2019**, San Antonio, Texas, USA, Poster 38. *Poster presentation*.
  - Leonardi, C.; Pittalà, V.; Ciaffaglione, V.; Fallica, A. N.; **Intagliata, S.**; Abdelghany, S.; Khalaf, N.B. Computer-aided approach to design protein Leishmania major Disulfide Isomerase (LmPDI) inhibitors. Congresso Congiunto delle Sezioni Sicilia e Calabria 2019. Mar. 1-2, **2019**, Palermo, Italia, P-24. *Poster presentation*.
  - Ciaffaglione, V.; Fallica, A. N.; Leonardi, C.; **Intagliata, S.**; Dichiarà, M.; Barbaraci, C.; Carota, G.; Salerno, L. Development of novel azole-based Heme Oxygenase-1 Inhibitors. Congresso Congiunto delle Sezioni Sicilia e Calabria 2019. Mar. 1-2, **2019**, Palermo, Italia, P-11. *Poster presentation*.
  - **Intagliata, S.**; Pittalà, V.; Salerno, L.; Cagnotto, A.; Romeo, G.; Amata, E.; Marrazzo, A.; Modica M.N. New homo and hetero bis-arylpiperazine and bis-benzylpiperazine derivatives as 5-HT<sub>7</sub>R selective ligands: design and synthesis. Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry, MedChemSicily, July 17-20, **2018**, Palermo, Italia, P-94. *Poster presentation*.
  - Dichiarà, M.; Barbaraci, C.; Gentile, D.; **Intagliata, S.**; Pittalà, V.; Arena, E.; Fraix, A.; Farina, G.; Prezzavento, O.; Amata, E.; Marrazzo A. Design, synthesis, and pharmacological evaluation of NO donor-sigma receptors hybrids for the treatment of cancer. Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry, MedChemSicily, July 17-20, **2018**, Palermo, Italia, P-52. *Poster presentation*.
  - Montenegro, L.; **Intagliata, S.**; Salerno, L.; Romeo, G.; Pittalà, V.; Siciliano, E.; Panico, A.M.; Modica M.N. Synthesis and in vitro antioxidant activity of a novel idebenone ester with pyroglutamic acid. Italian-Spanish-Portuguese Joint Meeting in Medicinal Chemistry, MedChemSicily, July 17-20, **2018**, Palermo, Italia, P-71. *Poster presentation*.
  - **Intagliata, S.**; Kopajtic, T.A.; Katz, J. L.; Ganno, M. L.; Sharma, A.; Avery, B.A.; Eans, S.O.;



- McLaughlin, J.P.; McCurdy, C.R. Multidisciplinary Approach in the Optimization of a Highly Selective Sigma-1 Receptor Antagonist. International Narcotic research Conference. June 12-16, **2018**, San Diego, California, USA. P-33. *Poster presentation.*
- Montenegro, L.; Salerno, L.; Romeo, G.; Pittalà, V.; **Intagliata, S.**; Macaluso, B.; Panico, A.M.; Crascì, L.; Modica, M.N. Caratterizzazione chimico-fisica ed attività antiossidante in vitro del triestere trans-resveratrolo trolox. Congresso Congiunto delle Sezioni Sicilia-Calabria 2018. Feb. 9-10, **2018**, Catania, Italy, P09. *Poster presentation.*
  - **Intagliata, S.**; Kopajtic, T.A.; Katz, J. L.; Ganno, M. L.; Sharma, A.; Avery, B.A.; Eans, S.O.; McLaughlin, J.P.; McCurdy, C.R. Investigation of Structure Activity Relationships in the Optimization of a Highly Selective Sigma-1 Receptor Antagonist. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. Nov. 12-15, **2017**, San Diego, California, USA, P-M7047. *Poster presentation.*
  - Modica, M.N.; Salerno, L.; **Intagliata, S.**; Romeo, G.; Pittalà, V.; Panico, A.M.; Crascì, L.; Puglisi, G.; Montenegro, L. Attività antiossidante in vitro di derivati dell'idebenone. Workshop delle sezioni Sicilia-Calabria SCI, Feb. 9-10, **2017**, Messina, Italia, CO-13. *Oral presentation.*
  - Romeo, G.; Pittalà, V.; Salerno, L.; Modica, M.N.; Candido, M.; **Intagliata, S.**; Marrazzo, A.; Amata, E.; Cagnotto, A.; Salmona, M.; Siracusa, M.A. Novel selective ligands for the serotonergic 5-HT<sub>7</sub> receptor: tricyclic derivatives bearing the pyrimido-4(3H)-one ring. XXIV NMMC & 10<sup>th</sup> NPCF. Sept. 11-14, **2016**, Perugia, Italia, PC-131. *Poster presentation.*
  - Romeo, G.; Modica, M.N.; Salerno, L.; Pittalà, V.; **Intagliata, S.**; Cagnotto, A.; Salmona, M.; Siracusa, M.A. Thieno[3,2-d]pyrimidine as a scaffold for 5-HT<sub>7</sub> receptor ligands. XXV Congresso della Società Chimica Italiana. SCI-2014. Sept. 7-12, **2014**, Arcavacata di Rende, Cosenza, Italia, P-370. *Poster presentation.*
  - Modica, M.N.; **Intagliata, S.**; Romeo, G.; Pittalà, V.; Salerno, L.; Siracusa, M.A.; Cagnotto, A. New thienopyrimidine and quinazoline derivatives as potential 5-HT<sub>7</sub> receptor ligands. Polish-Austrian-Czech-Germany-Greek-Hungarian-Italian-Slovak-Slovenian VIIIth Joint Meeting on Medicinal Chemistry, Lublin, Poland, June 30-July 4, **2013**, P-31. *Poster presentation.*

## TEACHING ACTIVITIES

Academic Year 2019/2020 –to date Course lecturer of “Laboratorio di Biotecnologie Farmaceutiche, c.i., corso M-Z (S.S.D. CHIM/08, 6 CFU)”. Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche – 5° anno, Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania

## MENTORING AND PhD SUPERVISION

- Academic years 2019/2021: Co-supervisor of the Ph.D. thesis entitles “Modulation of heme oxygenase-1 activity by novel synthetic compounds for pharmacological applications.” Ph.D. student: Valeria Ciaffaglione, Dottorato Internazionale in Scienze Chimiche, XXXIV ciclo, Università degli Studi di Catania.
- From 2019 – to date: Supervisor of 3 experimental Master’s theses (Laurea Magistrale in Farmacia and CTF).
- From 2014 – to date: Co-supervisor of 5 experimental Master’s theses (Laurea Magistrale in Farmacia and CTF).

## INSTITUTIONAL ROLES

- Jul. 2022 – present: Member of the management committee for the NMR instrumentation of the Department of Drug and Health Sciences, University of Catania, University of Catania, Italy, DSFS, Unict.
- Nov. 2021 – present: Member of the working group for the Internationalization mobility of the Department of Drug and Health Sciences, University of Catania, University of Catania, Italy.

**EDITORIAL ACTIVITY**

- Guest Editor for the Special Issue entitled "New Strategies and Approaches in Polypharmacology" of *Molecules*, Medicinal Chemistry section, MDPI AG, Basel, Switzerland, (JCR - Q2 Chemistry, Multidisciplinary/ CiteScore - Q1 Chemistry, miscellaneous; IF 2021 = 4.927). ISSN: 1420-3049.
- Guest Editor for the Special Issue entitled "Hybrid Compounds, Multitarget Ligands, and Conjugate Derivatives as New Targeted Anticancer Agents" of *Molecules*, Medicinal Chemistry section, MDPI AG, Basel, Switzerland, (JCR - Q2 Chemistry, Multidisciplinary/CiteScore - Q2 Chemistry, miscellaneous; IF 2020 = 4.411). ISSN: 1420-3049.

**PROFESSIONAL SERVICE (Peer Review)**

Dic. 2019 – Presente	<i>Biomolecules</i> , MDPI AG, Basel, Switzerland. ISSN 2218-273X
Jul. 2019 – Present	<i>Eur. J. Med. Chem.</i> Elsevier. ISSN: 0223-5234
Jan. 2019 – Present	<i>Molecules</i> , MDPI AG, Basel, Switzerland. ISSN 1420-3049
Apr. 2018 – Present	<i>Medicinal Chemistry Research</i> , Springs. ISSN: 1054-2523
Apr. 2017 – Present	<i>Bioorganic &amp; Medicinal Chemistry</i> , Elsevier. ISSN: 0968-0896
Oct. 2016 – Present	<i>Med. Chem. Comm.</i> , Royal Society of Chemistry. ISSN: 2040-2503
Dec. 2016 – Present	<i>Letters in Organic Chemistry</i> , Bentham Science. ISSN: 1570-1786

**AWARDS**

Apr. 2019	Winner best oral presentations, PostDoc category. CNPD3 UF Drug Discovery Symposium 2019. Gainesville, FL, USA. April 25-26, <b>2019</b> .
Mar. 2019	EFMC Grant to attend EFMC-ACSMEDI MedChem Frontiers 2019, Joint Symposium on Medicinal Chemistry Frontiers, Kracow, Poland, June 10-13, <b>2019</b> .
Jun. 2018	INRC Travel Award. International Narcotic Research Conference, 2018 Annual meeting, San Diego, CA, USA, June 12-16, <b>2018</b> .
Sept. 2014	Travel Award. XXV National Meeting of the Italian Chemical Society, SCI-2014. September 7-12, <b>2014</b> . Arcavacata di Rende, Cosenza, Italy.

**MEMBERSHIPS OF SCIENTIFIC SOCIETIES**

Jun. 2018 – Present	ACS Division of Medicinal Chemistry (ACS MEDI).
Sept. 2017 – Present	American Association of Pharmaceutical Sciences (AAPS).
Feb. 2017 – Present	National Postdoctoral Association (NPA).
July 2014 – Present	Division of Medicinal Chemistry of the Italian Chemical Society.

Last update: Feb. 10, 2023.